Journal: Materials Today Bio

Article Title: A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

doi: 10.1016/j.mtbio.2025.101801

Figure Lengend Snippet: Graphical illustration of the immunization strategy of GBE@LP for liver cancer treatment. GBE@LP has prolonged circulation in the bloodstream due to surface PEG and selectively accumulates in liver cancer tissues through EPR effect. Meanwhile, DOPE and TGMS give it the property to be released in response to low pH and MMP-9 overexpression in liver cancer microenvironment. GBE@LP delivers drugs into liver cancer, converting uninfiltrated "cold" tumors into highly infiltrated "hot" tumors, while reversing CD8 + T-cell depletion and enhancing cytotoxicity. These effects ultimately enhance immunotherapy for liver cancer.

Article Snippet: After deparaffinization and rehydration, the sections were microwaved in 0.01M sodium citrate (pH 6) for 8 min, followed by blocking with 5 % bovine serum albumin (BSA) for 1 h. The sections were then incubated with anti-mouse CD8, anti-mouse PD-1, and anti-mouse AR antibodies (all from Proteintech) at 4 °C for 12 h. After washing, the sections were incubated with Dylight 649 (Goat Anti-Mouse IgG) and Dylight 488 (Goat Anti-Rabbit IgG) antibodies (all from Abbkine) for 1 h, stained with DAPI for 5 min, and then mounted.

Techniques: Over Expression

Journal: Materials Today Bio

Article Title: A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

doi: 10.1016/j.mtbio.2025.101801

Figure Lengend Snippet: Liver cancer is a "cold" tumor with high Gal-3 expression. (A) Immunofluorescence images of CD8 + T cells (red) and DAPI (blue) in liver cancer tissues of tumor-bearing mice. (B) Immunohistochemical images of cd8 + T cells in patients with hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and lung cancer (LC) from the HPA database. (C) Expression of Gal-3 in different human cancers was analyzed by HPA database. (D) The expression of Gal-3 in mouse liver cancer tissues and paracancerous tissues was detected by western blotting. (E) The expression of CD8 in the control group and GB1107 treatment group was detected by western blotting. (F) Immunofluorescence images of CD8 + T cells (green), PD-1 (red), and DAPI (blue) in liver cancer tissues and paracancerous tissues of tumor-bearing mice. (G) Immunofluorescence images of CD8 + T cells (green), AR (red), and DAPI (blue) in liver cancer tissues and paracancerous tissues of tumor-bearing mice.

Article Snippet: After deparaffinization and rehydration, the sections were microwaved in 0.01M sodium citrate (pH 6) for 8 min, followed by blocking with 5 % bovine serum albumin (BSA) for 1 h. The sections were then incubated with anti-mouse CD8, anti-mouse PD-1, and anti-mouse AR antibodies (all from Proteintech) at 4 °C for 12 h. After washing, the sections were incubated with Dylight 649 (Goat Anti-Mouse IgG) and Dylight 488 (Goat Anti-Rabbit IgG) antibodies (all from Abbkine) for 1 h, stained with DAPI for 5 min, and then mounted.

Techniques: Expressing, Immunofluorescence, Immunohistochemical staining, Western Blot, Control

Journal: Materials Today Bio

Article Title: A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

doi: 10.1016/j.mtbio.2025.101801

Figure Lengend Snippet: GBE@LP remodeling the immunosuppressive microenvironment of liver cancer. (A) Flow cytometry scatter graph and (C) Flow cytometry statistical plot of CD8 + T cells infiltration in the tumors of different treatment groups. (B) Flow cytometry histogram and (D) Flow cytometry statistical plot of CD3 + T cells infiltration in the spleen of different treatment groups. (n = 3, p ∗ < 0.05, p ∗∗ < 0.01, p ∗∗∗ < 0.001, p ∗∗∗∗ < 0.0001).

Article Snippet: After deparaffinization and rehydration, the sections were microwaved in 0.01M sodium citrate (pH 6) for 8 min, followed by blocking with 5 % bovine serum albumin (BSA) for 1 h. The sections were then incubated with anti-mouse CD8, anti-mouse PD-1, and anti-mouse AR antibodies (all from Proteintech) at 4 °C for 12 h. After washing, the sections were incubated with Dylight 649 (Goat Anti-Mouse IgG) and Dylight 488 (Goat Anti-Rabbit IgG) antibodies (all from Abbkine) for 1 h, stained with DAPI for 5 min, and then mounted.

Techniques: Flow Cytometry

Journal: Materials Today Bio

Article Title: A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

doi: 10.1016/j.mtbio.2025.101801

Figure Lengend Snippet: (A) Immunofluorescence images of CD8 + T cells (green) and DAPI (blue) in different treatment groups. Scale bars, 1000 μm (top), 50 μm (bottom).

Article Snippet: After deparaffinization and rehydration, the sections were microwaved in 0.01M sodium citrate (pH 6) for 8 min, followed by blocking with 5 % bovine serum albumin (BSA) for 1 h. The sections were then incubated with anti-mouse CD8, anti-mouse PD-1, and anti-mouse AR antibodies (all from Proteintech) at 4 °C for 12 h. After washing, the sections were incubated with Dylight 649 (Goat Anti-Mouse IgG) and Dylight 488 (Goat Anti-Rabbit IgG) antibodies (all from Abbkine) for 1 h, stained with DAPI for 5 min, and then mounted.

Techniques: Immunofluorescence

Journal: Asian Journal of Pharmaceutical Sciences

Article Title: Lignin-assisted construction of sub-10 nm supramolecular self-assembly for photothermal immunotherapy and potentiating anti-PD-1 therapy against primary and distant breast tumors

doi: 10.1016/j.ajps.2022.07.002

Figure Lengend Snippet: In vivo immune responses assessment. (A) Flow cytometry assay of CD80 + or CD86 + gated on CD11c + in the TDLNs of mice. (B) Flow cytometry assay illustrated the percent of CD8a + T cells and CD4 + T cells gated on CD3 + T cells in splenocytes of mice. (C-D) Quantitative percentages of CD80 + or CD86 + expressions gated on CD11c + according to (A). (E) Quantitative percentages of CD8a + T cells and CD4 + T cells in splenocytes according to (B). (F-H) Quantitative analysis of the immune-associated cytokines in serum, as determined by ELISA (IL-2, TNF-α and IFN-γ). ( n = 3, mean ± SD, * P < 0.05, ** P < 0.01 and ## P < 0.0001).

Article Snippet: Fluorochrome-labeled anti-mouse monoclonal antibodies (CD11c-allophycocyanin (APC), CD80-fluorescein isothiocyanate (FITC), CD86-phycoerythrin (PE), CD3-FITC, CD8a-PE, and CD4-APC) were bought from Proteintech.

Techniques: In Vivo, Flow Cytometry, Enzyme-linked Immunosorbent Assay

Journal: Scientific Reports

Article Title: Mitigation of Tacrolimus-Associated Nephrotoxicity by PLGA Nanoparticulate Delivery Following Multiple Dosing to Mice while Maintaining its Immunosuppressive Activity

doi: 10.1038/s41598-020-63767-1

Figure Lengend Snippet: In vivo suppression of T cell proliferation in male mice following a daily subcutaneous injection (for 7 days) of either (1) Normal Saline, (2) Empty PLGA NPs, (3) Prograf, or (4) TAC-loaded PLGA NPs. Flow cytometry analysis was conducted on two cell groups: ( A ) CD4 + T cells and ( B ) CD8 + T cells (n = 6). The percentage of proliferating T cells is presented next to each gate. All samples are composed of the same number of acquired events (10 6 cells).

Article Snippet: Standard surface staining protocol was followed for CD4 + and CD8 + T cells using anti-mouse CD4–APC (R&D systems) and CD8-PE-CY7 (R&D systems) monoclonal antibodies.

Techniques: In Vivo, Injection, Saline, Flow Cytometry